BeOne Medicines (ONC) CEO discloses mandatory tax withholding ADS sales
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
BeOne Medicines Ltd. director and CEO John Oyler reported transactions involving American Depositary Shares (ADSs) tied to his equity compensation. On June 23, 2026, entities associated with him disposed of a total of 3,410 ADSs in open-market sales at weighted average prices between $272.655 and $275.21.
Each ADS represents 13 Ordinary Shares. Footnotes state these sales were effected under a mandatory tax withholding provision in his restricted share unit award agreement upon vesting, rather than as discretionary sales. Following these transactions, Oyler holds 5,605,310 Ordinary Shares directly and additional Ordinary Shares indirectly through various trusts and an LLC, while he disclaims beneficial ownership of certain trust-held securities.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 3,410 shares ($933,592)
Net Sell
9 txns
Insider
OYLER JOHN
Role
Chief Executive Officer
Sold
3,410 shs ($934K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | American Depositary Shares | 1,800 | $273.3049 | $492K |
| Sale | American Depositary Shares | 1,290 | $274.1186 | $354K |
| Sale | American Depositary Shares | 320 | $275.095 | $88K |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
American Depositary Shares — 1,610 shares (Direct, null);
Ordinary Shares — 5,605,310 shares (Direct, null);
Ordinary Shares — 481,533 shares (Indirect, See Footnote)
Footnotes (1)
- These securities are held by the P&O Trust, the beneficiaries of which include the Reporting Person's child and others, for which the Reporting Person disclaims beneficial ownership. These securities are held in a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership. These securities are held by Oyler Investment LLC, of which 99% of the limited liability company interests owned by a grantor retain annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership. These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account. These securities are held by The John Oyler Legacy Trust for the benefit of the Reporting Person's child, for which the Reporting Person disclaims beneficial ownership. Each American Depositary Share represents 13 Ordinary Shares. The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon change of control or certain termination events. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $272.655 to $273.62, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $273.74 to $274.68, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.93 to $275.21, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
Key Figures
ADSs sold: 3,410 ADSs
ADS sale tranche 1: 1,800 ADSs at $273.3049
ADS sale tranche 2: 1,290 ADSs at $274.1186
+3 more
6 metrics
ADSs sold
3,410 ADSs
Open-market sales on June 23, 2026 for tax withholding
ADS sale tranche 1
1,800 ADSs at $273.3049
Weighted average sale price on June 23, 2026
ADS sale tranche 2
1,290 ADSs at $274.1186
Weighted average sale price on June 23, 2026
ADS sale tranche 3
320 ADSs at $275.0950
Weighted average sale price on June 23, 2026
Direct Ordinary Shares
5,605,310 shares
Ordinary Shares held directly following transactions
ADS to Ordinary ratio
1 ADS = 13 Ordinary Shares
Equivalence disclosed in footnote
Key Terms
American Depositary Shares, grantor retained annuity trust, Roth IRA PENSCO trust account, restricted share unit award, +1 more
5 terms
grantor retained annuity trust financial
"These securities are held in a grantor retained annuity trust, of which the Reporting Person's father is a trustee..."
A grantor retained annuity trust (GRAT) is an estate-planning tool where the person who creates the trust transfers assets into it but receives fixed cash payments (an annuity) from the trust for a set number of years; whatever remains after that term passes to designated beneficiaries. It matters to investors because it can shift future appreciation of assets out of the creator’s taxable estate—like putting an asset into a timed vending machine that pays you fixed amounts while any extra value that grows inside the machine goes to heirs with reduced gift or estate tax consequences.
Roth IRA PENSCO trust account financial
"These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account."
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
FAQ
What did BeOne Medicines (ONC) CEO John Oyler report in this Form 4?
John Oyler reported mandatory tax-related dispositions of 3,410 American Depositary Shares on June 23, 2026. These ADS sales were linked to vesting of a restricted share unit award and executed as open-market transactions at weighted average prices around $273–$275 per ADS.
How many BeOne Medicines (ONC) ADSs did John Oyler dispose of and at what prices?
Entities associated with John Oyler disposed of 3,410 American Depositary Shares in three tranches: 1,800 ADSs at $273.3049, 1,290 ADSs at $274.1186, and 320 ADSs at $275.0950. Footnotes explain each reported price is a weighted average over specified intraday ranges.
Were John Oyler’s BeOne Medicines (ONC) ADS transactions discretionary sales?
The filing indicates the ADS sales resulted from a mandatory tax withholding provision in Oyler’s restricted share unit award agreement. Shares were sold automatically to cover taxes upon vesting, so they do not represent discretionary portfolio decisions or a change in his investment view.
What BeOne Medicines (ONC) equity does John Oyler hold after these transactions?
After the reported transactions, John Oyler holds 5,605,310 Ordinary Shares directly. Additional Ordinary Shares are held indirectly through trusts, an investment LLC, and a Roth IRA account, and he disclaims beneficial ownership of certain trust-held positions according to the filing’s footnotes.